Bluejay Therapeutics Announces Expansion of Leadership Team and Board of Directors [Yahoo! Finance]
ALX Oncology Holdings Inc. (ALXO)
Company Research
Source: Yahoo! Finance
therapies for viral hepatitis and other serious liver diseases, today announced the expansion of its leadership team and board of directors. This news follows the company's recent announcement of new data from its Phase 2 study of BJT-778, a best-in class investigational, fully human, high-affinity monoclonal antibody (mAb) that targets hepatitis B virus surface antigen (anti-HBsAg), as a potential monotherapy for adults with chronic hepatitis D (CHD). Bluejay is advancing BJT-778 into larger, randomized controlled studies. “The expansion of our management team and board adds financial, commercial and business development leadership as we move quickly to advance our innovative lead asset, BJT-778, into pivotal trials,” said Keting Chu, M.D., Ph.D., Founder and Chief Executive Officer of Bluejay Therapeutics. “We are building our organization to accelerate the development of BJT-778 and meet the goal of improving patients' lives.” The new additions to the Bluejay Therapeutics lea
Show less
Read more
Impact Snapshot
Event Time:
ALXO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALXO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALXO alerts
High impacting ALX Oncology Holdings Inc. news events
Weekly update
A roundup of the hottest topics
ALXO
News
- ALX Oncology Appoints Alan Sandler, M.D., as Chief Medical Officer [Yahoo! Finance]Yahoo! Finance
- ALX Oncology Appoints Alan Sandler, M.D., as Chief Medical OfficerGlobeNewswire
- ALX Oncology Holdings Inc. (NASDAQ: ALXO) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.MarketBeat
- ALX Oncology Reports Third Quarter 2024 Financial Results and Provides Corporate UpdateGlobeNewswire
- ALX Oncology Announces November Investor Conference ParticipationGlobeNewswire
ALXO
Earnings
- 11/7/24 - Beat
ALXO
Sec Filings
- 11/19/24 - Form 4
- 11/14/24 - Form SC
- 11/14/24 - Form SC
- ALXO's page on the SEC website